The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center established in 2004. Its stakeholders are Bellvitge University Hospital and Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, University of Barcelona and the town council of L’Hospitalet de Llobregat.
IDIBELL is located in L’Hospitalet de Llobregat, south of Barcelona. It is a member of the Campus of International Excellence of the University of Barcelona HUBc and part of the CERCA institution of the Generalitat of Catalonia. In 2009, it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Institute of Health. Recently, IDIBELL has been certified with the “HR Excellence” logo which recognizes IDIBELL as a center with a policy for a correct professional development.
Bellvitge Institute for Biomedical Research (IDIBELL) offers a postdoctoral contract to join the Transformation and Metastasis group led by Dr. Eva González-Suárez within the Cancer Epigenetics and Biology Program (PEBC) http://www.idibell.cat & http://pebc.cat/, in Barcelona, Spain.
The laboratory of Dr Gonzalez Suarez is funded by national grants and a European Research Council ERC-Consolidator grant.
The primary goal of Dr. Eva González-Suárez´s laboratory is to understand the signaling pathways implicated in epithelial stem cell fate, their alterations during cancer and metastasis, and the interactions between tumor cells and microenvironment. We have a multidisciplinary approach using mouse models, cell cultures, clinical samples and molecular and cell biology techniques to translate basic research into clinically relevant results.